Margi McLoughlin
Executive Director @ Pfizer
San Francisco Bay Area, United States
Margi McLoughlin is a Series A investor at Pfizer in San Francisco Bay Area focused on Biotechnology and Medical. Margi McLoughlin, PHD is Executive Director, WWBD and Partner at Pfizer Ventures. Margi invests in companies working in areas aligned with the future directions of Pfizer. She currently has responsibility for Pfizer’s investments in 4D Molecular Therapeutics, Adapsyn, BioAtla, Cortexyme and System1. Through these investments, she works with thecompanies to help advance products and technologies of value to the pharmaceutical industry.Margi began her career at Mallinckrodt Medical, holding positions in Discovery Research, followed by Technology Planning. In 1999, she moved to Yale University where she worked as Associate Director in the Office of Cooperative Research. Since joining Pfizer Worldwide Business Development in 2001, she has had roles of increasing responsibility and led transactions with multiple biotech companies, including Ablexis, Gliknik and Excaliard. In addition, Margi played a significant role in defining Pfizer’s Centers for Therapeutic Innovation business model.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Margi McLoughlin invests in
Stages Margi McLoughlin invests in
Countries Margi McLoughlin invests in
Investment Focus
Industry
- Biotechnology 2 (100%)
- Medical 1 (50%)
- Health Care 1 (50%)
- Pharmaceutical 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
System1 Biosciences
|
System1 Biosciences, Inc., is a San Francisco-based neurotherapeutics company that employs phenotypic screening to discover novel drugs for complex neurological and psychiatric diseases such as epilepsy, autism, and schizophrenia, disorders for which current discovery techniques have proved least successful. System1 combines cerebral organoidscience, systems neuroscience, robotic automation, and advanced data analytics to discover characterizations of disease never before achievable. These “deep phenotypes” are exploited to identify novel therapeutic targets and drug treatments. | $25M / Series A / Sep 12, 2018 | |
Quince Therapeutics
|
Cortexyme is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currentlytesting several potential lead therapeutics in preclinical studies. | $15M / Series A / Jan 06, 2016 |
Co-Investors
About Pfizer
Pfizer provides access to safe and effective and affordable medicines and health care services. They have a portfolio of products and medicines that support wellness and prevention, as well as treatment and cures for diseases across a broad range of therapeutic areas; and they have an industry-leading pipeline of promising new products that havethe potential to challenge some of the most feared diseases of their time, like Alzheimer's disease and cancer.
Pfizer Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alessandra Leone
Global CMC Sr. Manager
|
|||
|
Angela L Coral
Senior Manager, Partnerships & Impact Reporting, Global Health & Social Impact
|
|||
Barbara Dalton
Senior Managing Partner, Pfizer Ventures; VP, Worldwide Business Development
|
|||
Chris Boshoff
CSO
|
|||
Chris O’Donnell
Partner, Pfizer Ventures & Executive Director, Emerging Sciences & Innovation
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Margi McLoughlin invest in?
Margi McLoughlin invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Margi McLoughlin last invest?
The most recent investment recorded for Margi McLoughlin closed in Sep 2018. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
